LABELS · 473a8026-e822-2a9e-e063-6294a90a5c06

Rubraca

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-12-31
Captured: 2026-09-09T23:37:44.904352+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].

Full extracted label fields

application numbers

NDA209115

boxed warning exact

brand names

Rubraca

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0295d202-1cfe-7659-e063-6294a90a476e

generic names

RUCAPARIB

473a8026-e822-2a9e-e063-6294a90a5c06

indications and usage exact

1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].

indications and usage tables exact

is original packager

true

manufacturer names

pharmaand GmbH

matched search terms

cancer

package ndcs

82154-0783-1
82154-0785-1
82154-0784-1

product ndcs

82154-0783
82154-0785
82154-0784

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1.2 ) 12/2025 Warnings and Precautions ( 5.1 ) 12/2025

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

1862584
1862590
1862593
1862595
1921587
1921589

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00200.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA209115

brand names

Rubraca

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 575
end exclusive: true
exact text: 1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 0

current approval status

not_reconciled

duplicate text group

dup-5148a0b5baf1677689fc

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-44a4633b1643f5a95c1c

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

end: 92
end exclusive: true
exact text: is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 32

qualifier mentions

context exact
indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-
kind
age
polarity
not_inferred
span
end
156
end exclusive
true
exact text
adult patients
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
142
context exact
maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or prim
kind
biomarker
polarity
not_inferred
span
end
220
end exclusive
true
exact text
BRCA mutation (germline and/or somatic)-asso
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
176
context exact
eterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a
kind
stage_or_setting
polarity
not_inferred
span
end
255
end exclusive
true
exact text
recurrent epithelial ovarian
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
227

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 375
end exclusive: true
exact text: 1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA209115

brand names

Rubraca

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 824
end exclusive: true
exact text: BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the m
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 176

current approval status

not_reconciled

duplicate text group

dup-ff7bdd50abb33634cdf9

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-af5ffd7a3aadb4484e10

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

end: 92
end exclusive: true
exact text: is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 32

qualifier mentions

context exact
( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-
kind
age
polarity
not_inferred
span
end
435
end exclusive
true
exact text
adult patients
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
421
context exact
ncer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRP
kind
biomarker
polarity
not_inferred
span
end
499
end exclusive
true
exact text
BRCA mutation (germline and/or somatic)-asso
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
455
context exact
eterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-di
kind
biomarker
polarity
not_inferred
span
end
549
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
506
context exact
eterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-dire
kind
stage_or_setting
polarity
not_inferred
span
end
551
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
506

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 624
end exclusive: true
exact text: ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 376

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · unclassified context

application numbers

NDA209115

brand names

Rubraca

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 911
end exclusive: true
exact text: t patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/o
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 425

current approval status

not_reconciled

duplicate text group

dup-907b5c7e7b1505fdae47

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-1ec57d2343bf141282bb

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 711
end exclusive: true
exact text: Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 625

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA209115

brand names

Rubraca

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 925
end exclusive: true
exact text: atic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-ass
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 512

current approval status

not_reconciled

duplicate text group

dup-d02b8c543ab02b4c8403

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-c552d95e329b3abbacd8

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 725
end exclusive: true
exact text: ( 1.2 , 2.1 )
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 712

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · positive indication candidate

application numbers

NDA209115

brand names

Rubraca

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1281
end exclusive: true
exact text: n-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metast
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 526

current approval status

not_reconciled

duplicate text group

dup-d2f1f7100cca8819222a

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-999b112fb070d9f3c684

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

end: 814
end exclusive: true
exact text: is indicated
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 802

qualifier mentions

context exact
ancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-
kind
age
polarity
not_inferred
span
end
862
end exclusive
true
exact text
adult patients
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
848
context exact
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patie
kind
biomarker
polarity
not_inferred
span
end
799
end exclusive
true
exact text
BRCA -mutated Recurrent Ovarian Cancer RUBRA
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
755
context exact
maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or prim
kind
biomarker
polarity
not_inferred
span
end
926
end exclusive
true
exact text
BRCA mutation (germline and/or somatic)-asso
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
882
context exact
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a del
kind
stage_or_setting
polarity
not_inferred
span
end
813
end exclusive
true
exact text
Recurrent Ovarian Cancer RUBRACA is indicate
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
769
context exact
eterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a
kind
stage_or_setting
polarity
not_inferred
span
end
961
end exclusive
true
exact text
recurrent epithelial ovarian
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
933

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1081
end exclusive: true
exact text: 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 726

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

NDA209115

brand names

Rubraca

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1520
end exclusive: true
exact text: BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 882

current approval status

not_reconciled

duplicate text group

dup-c7e68190278b26df63b2

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-6b7629224953e19e75da

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

end: 1168
end exclusive: true
exact text: is indicated
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 1156

qualifier mentions

context exact
t Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-
kind
age
polarity
not_inferred
span
end
1204
end exclusive
true
exact text
adult patients
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
1190
context exact
1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of
kind
biomarker
polarity
not_inferred
span
end
1130
end exclusive
true
exact text
BRCA -mutated Metastatic Castration-Resistan
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
1086
context exact
ated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRP
kind
biomarker
polarity
not_inferred
span
end
1268
end exclusive
true
exact text
BRCA mutation (germline and/or somatic)-asso
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
1224
context exact
eterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-di
kind
biomarker
polarity
not_inferred
span
end
1318
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
1275
context exact
1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients
kind
stage_or_setting
polarity
not_inferred
span
end
1145
end exclusive
true
exact text
Metastatic Castration-Resistant Prostate Canc
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
1100
context exact
eterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-dire
kind
stage_or_setting
polarity
not_inferred
span
end
1320
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start
1275

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1393
end exclusive: true
exact text: 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 1082

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · unclassified context

application numbers

NDA209115

brand names

Rubraca

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1520
end exclusive: true
exact text: t patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 1194

current approval status

not_reconciled

duplicate text group

dup-8899883bdcfd49f6495e

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-2533f02884c6a2adf9ea

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 1520
end exclusive: true
exact text: Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 706ee44786cb0d4616e40364af08c8bf7a8f27acb808d469e5539193432b947b
start: 1394

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA209115

brand names

Rubraca

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 355
end exclusive: true
exact text: 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 1
source field: indications_and_usage_exact
source text sha256: 37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start: 0

current approval status

not_reconciled

duplicate text group

dup-d2f1f7100cca8819222a

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-91620d9afb5db9018c32

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

end: 88
end exclusive: true
exact text: is indicated
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 1
source field: indications_and_usage_exact
source text sha256: 37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start: 76

qualifier mentions

context exact
ancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-
kind
age
polarity
not_inferred
span
end
136
end exclusive
true
exact text
adult patients
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
1
source field
indications_and_usage_exact
source text sha256
37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start
122
context exact
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patie
kind
biomarker
polarity
not_inferred
span
end
73
end exclusive
true
exact text
BRCA -mutated Recurrent Ovarian Cancer RUBRA
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
1
source field
indications_and_usage_exact
source text sha256
37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start
29
context exact
maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or prim
kind
biomarker
polarity
not_inferred
span
end
200
end exclusive
true
exact text
BRCA mutation (germline and/or somatic)-asso
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
1
source field
indications_and_usage_exact
source text sha256
37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start
156
context exact
1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a del
kind
stage_or_setting
polarity
not_inferred
span
end
87
end exclusive
true
exact text
Recurrent Ovarian Cancer RUBRACA is indicate
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
1
source field
indications_and_usage_exact
source text sha256
37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start
43
context exact
eterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a
kind
stage_or_setting
polarity
not_inferred
span
end
235
end exclusive
true
exact text
recurrent epithelial ovarian
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
1
source field
indications_and_usage_exact
source text sha256
37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start
207

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 355
end exclusive: true
exact text: 1.1 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer RUBRACA is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 1
source field: indications_and_usage_exact
source text sha256: 37d0108a4c3e741817448cd906eda1bbe4a52c966ff6280294639a28fdcfae32
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

NDA209115

brand names

Rubraca

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 438
end exclusive: true
exact text: 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 2
source field: indications_and_usage_exact
source text sha256: e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start: 0

current approval status

not_reconciled

duplicate text group

dup-c7e68190278b26df63b2

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-cf4eb202c73d66abee8e

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

end: 86
end exclusive: true
exact text: is indicated
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 2
source field: indications_and_usage_exact
source text sha256: e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start: 74

qualifier mentions

context exact
t Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-
kind
age
polarity
not_inferred
span
end
122
end exclusive
true
exact text
adult patients
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
2
source field
indications_and_usage_exact
source text sha256
e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start
108
context exact
1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of
kind
biomarker
polarity
not_inferred
span
end
48
end exclusive
true
exact text
BRCA -mutated Metastatic Castration-Resistan
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
2
source field
indications_and_usage_exact
source text sha256
e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start
4
context exact
ated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRP
kind
biomarker
polarity
not_inferred
span
end
186
end exclusive
true
exact text
BRCA mutation (germline and/or somatic)-asso
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
2
source field
indications_and_usage_exact
source text sha256
e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start
142
context exact
eterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-di
kind
biomarker
polarity
not_inferred
span
end
236
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
2
source field
indications_and_usage_exact
source text sha256
e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start
193
context exact
1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients
kind
stage_or_setting
polarity
not_inferred
span
end
63
end exclusive
true
exact text
Metastatic Castration-Resistant Prostate Canc
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
2
source field
indications_and_usage_exact
source text sha256
e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start
18
context exact
eterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-dire
kind
stage_or_setting
polarity
not_inferred
span
end
238
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
473a8026-e822-2a9e-e063-6294a90a5c06
offset unit
unicode_code_points
source array index
2
source field
indications_and_usage_exact
source text sha256
e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start
193

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 311
end exclusive: true
exact text: 1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy.
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 2
source field: indications_and_usage_exact
source text sha256: e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 10 · unclassified context

application numbers

NDA209115

brand names

Rubraca

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 438
end exclusive: true
exact text: t patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 2
source field: indications_and_usage_exact
source text sha256: e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start: 112

current approval status

not_reconciled

duplicate text group

dup-8899883bdcfd49f6495e

extraction review status

automated_candidate_pending_source_review

generic names

RUCAPARIB

ind-span-3aa62fc8b7a176694b63

label id

473a8026-e822-2a9e-e063-6294a90a5c06

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

source span

end: 438
end exclusive: true
exact text: Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA [see Dosage and Administration ( 2.1 )].
label id: 473a8026-e822-2a9e-e063-6294a90a5c06
offset unit: unicode_code_points
source array index: 2
source field: indications_and_usage_exact
source text sha256: e3eba422a3e244fc3f52128ec26c9530cb06a0ca7ecd30e2acd8fe0916aa69c3
start: 312

source url

https://api.fda.gov/drug/label.json?search=id%3A%22473a8026-e822-2a9e-e063-6294a90a5c06%22

spl effective date

2025-12-31

spl set id

0295d202-1cfe-7659-e063-6294a90a476e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice